Clinical trials: Phase III trial results for tofacitinib bring new oral DMARD therapy a step closer for patients with rheumatoid arthritis

Nature Reviews Rheumatology

Volumn 8, Issue 10, 2012, Pages 561-

  Leah, Emma ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; JANUS KINASE 1; JANUS KINASE 3; JANUS KINASE INHIBITOR; METHOTREXATE; PLACEBO; TOFACITINIB;

ARTHRALGIA; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE SEDIMENTATION RATE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MONOTHERAPY; NOTE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT;

EID: 84867082115     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2012.145     Document Type: Note

References (2)

1. Fleischmann, R.et al.Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.N.Engl.J.Med.367, 495-507 (2012)
2. van Vollenhoven, R.F.et al.Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.N.Engl.J.Med.367, 508-519 (2012)